Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Repair of this damage utilizes either single-strand break (SSB) or double-strand break (DSB) repair pathways. We and others have previously shown that inhibition of poly (ADP) ribose polymerase-1 ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

Boston (March 13, 2025)-Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

(“Allarity” or the“Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage Pharmaceutical company dedicated to developing stenoparib-a differentiated dual PARP/Wnt pathway inhibitor-today ...

The Fellows of the AACR Academy have elected Elaine V. Fuchs, PhD, FAACR, as their next President. She will assume the ...

Boston (March 13, 2025)-Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...

Big data analysis of ovarian cancer networks involved in metabolic, and inflammatory pathways.• Clinical translation strategies for ovarian cancer targeted therapeutics.• Non-coding RNA and targeted ...

Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated ...